FBB Biomed

Executive Summary

FBB Biomed is a San Diego-based biotechnology company founded in 2019 with a mission to develop a single, comprehensive blood test that tracks genomic health over a patient's lifetime. The company's initial focus is precision neurology, offering a non-invasive liquid biopsy to stratify patients with neurodegenerative diseases such as Alzheimer's and Parkinson's. By leveraging advanced genomic analysis from a simple blood draw, FBB Biomed aims to enable early detection, disease monitoring, and personalized treatment decisions. This approach has the potential to transform neurodegenerative disease management, which currently relies on invasive procedures and late-stage diagnosis. As a private company in the early stages of development, FBB Biomed is poised to address a significant unmet need in neurology diagnostics, though it has not yet disclosed clinical data or funding details.

Upcoming Catalysts (preview)

• Q4 2026Initial Clinical Proof-of-Concept Data40% success
• Q2 2026Strategic Partnership with Pharma or Diagnostics Company30% success
• Q3 2026Series A Funding Announcement50% success